Long-term intermittent netilmicin therapy of chronic pyelonephritis: a pharmacokinetic and clinical study.
A trial was conducted with long-term intermittent netilmicin therapy in six patients suffering from chronic pyelonephritis. Netilmicin was given in full dose for a period of 3-10 days (2-6 mg/kg/day), followed by 2 mg/kg doses once or twice weekly for 3-6 months. Individual doses were determined by computer based on the age, sex, lean body weight and serum creatinine concentrations of the patients. During the full-dose period of treatment netilmicin concentrations in serum were between 2 and 16 mg/l in serum and between 50 and 200 mg/l in urine. During intermittent treatment serum levels remained below 2 mg/l (except for 8-12 hours after dosing); in the urine concentrations were permanently in therapeutic ranges (150-4 mg/l). Renal tissue levels were simulated. Six to 12 months after long-term netilmicin treatment all patients are abacteriuric and free from symptoms. No auditory or renal toxic effects occurred.
D000328:Adult; D000368:Aged; D002851:Chromatography, High Pressure Liquid; D002908:Chronic Disease; D005260:Female; D005839:Gentamicins / Q000627:therapeutic use*; D006801:Humans; D007273:Injections, Intramuscular; D007700:Kinetics; D008297:Male; D008875:Middle Aged; D009428:Netilmicin / Q000378:metabolism / Q000627:therapeutic use*; D011704:Pyelonephritis / Q000188:drug therapy* / Q000378:metabolism
D005839:Gentamicins; D009428:Netilmicin